NRX Pharmaceuticals Inc. Logo
US6294442099

NRX Pharmaceuticals Inc.

Ins Portfolio
60% Chancen, 40% Gelassenheit. Aktien und Anleihen in einem LifeStrategy ETF. Jetzt entdecken
Anzeige

Kurse werden geladen...

 Anzeige

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +1,75(24,89%). Der Median liegt bei +1,75(24,89%).

Kaufen
  4
Halten
  0
Verkaufen
  0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News


  • NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Matthew Duffy – Chief Business Officer Jonathan Javitt – Founder, Chairman, and Chief Executive Officer Michael Abrams – Chief Financial Officer Conference Call Participants Tom Shrader – BTIG Ed Woo – Ascendiant Capital Operator Good afternoon, ladies and gentlemen, and welcome to the NRx Pharmaceuticals First Quarter 2025 Earnings Call. At this time, all lines are in a listen-only mode.» Mehr auf seekingalpha.com


  • NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update

    Company has continued to advance its previously announced plan to obtain FDA approval for two new drugs and to develop a network of clinics focused on neuroplastic therapies to treat severe and suicidal depression, PTSD, and related conditions. Clinic acquisition financing is at the HOPE Therapeutics level and non-dilutive to NRXP shareholders In January 2025 completed the third tranche of a convertible note offering and registered direct equity offering to an institutional investor on favorable terms to the Company; expected to provide sufficient cash to support operations through the end of 2025.» Mehr auf prnewswire.com


  • HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions

    Term sheet with Universal Capital, LLC to fund HOPE Therapeutics clinic acquisition strategy Funding tied to already-announced acquisitions, with additional tranches contemplated for further growth, subject to standard due diligence Together with previously announced term sheet with a strategic investor, HOPE funding of $10.3 million is planned in the near term  MIAMI , May 15, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced signing of a term sheet with Universal Capital, LLC ("Universal") to provide $7.8 million in acquisition capital to initiate HOPE's planned national rollup of interventional psychiatry clinics, commencing with previously-announced acquisitions of Dura Medical, Kadima, and NeuroSpa. Together with proceeds of a previously announced strategic investment, this financing is anticipated to provide $10.3 million in acquisition capital.» Mehr auf prnewswire.com

Unternehmenszahlen

Im letzten Quartal hatte NRX Pharmaceuticals Inc. einen Umsatz von 0,00 und ein Nettoeinkommen von 5,10 Mio
(EUR)März 2025
YOY
Umsatz0,00-
Bruttoeinkommen0,00100,00%
Nettoeinkommen5,10 Mio15,77%
EBITDA5,10 Mio12,68%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+39,99 Mio
Anzahl Aktien
17,29 Mio
52 Wochen-Hoch/Tief
+5,27 - +0,96
DividendenNein
Beta
1,45
KGV (PE Ratio)
1,80
KGWV (PEG Ratio)
0,11
KBV (PB Ratio)
1,72
KUV (PS Ratio)
+11.410,87

Unternehmensprofil

Name
NRX Pharmaceuticals Inc.
CEO
Dr. Jonathan C. Javitt M.D., M.P.H.
Mitarbeiter2
🍪

Parqet nutzt Cookies.Erfahre Mehr